p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells

Abstract

Interleukin-23 (IL-23), a heterodimeric cytokine of covalently bound p19 and p40 proteins, has recently been closely associated with development of several chronic autoimmune diseases such as psoriasis, psoriatic arthritis or inflammatory bowel disease. Released by activated dendritic cells, IL-23 interacts with IL-23 receptor (IL-23R) on Th17 cells, thus promoting intracellular signaling, a pivotal step in Th17-driven pro-inflammatory axis. Here, we aimed to block the binding of IL-23 cytokine to its cell-surface receptor by novel inhibitory protein binders targeted to the p19 subunit of human IL-23. To this goal, we used a combinatorial library derived from a scaffold of albumin-binding domain (ABD) of streptococcal protein G, and ribosome display selection, to yield a collection of ABD-derived p19-targeted variants, called ILP binders. From 214 clones analyzed by ELISA, Western blot and DNA sequencing, 53 provided 35 different sequence variants that were further characterized. Using in silico docking in combination with cell-surface competition binding assay, we identified a group of inhibitory candidates that substantially diminished binding of recombinant p19 to the IL-23R on human monocytic THP-1 cells. Of these best p19-blockers, ILP030, ILP317 and ILP323 inhibited IL-23-driven expansion of IL-17-producing primary human CD4⁺T-cells. Thus, these novel binders represent unique IL-23-targeted probes useful for IL-23/IL-23R epitope mapping studies and could be used for designing novel p19/IL-23-targeted anti-inflammatory biologics.

• Psoriasis
• autoimmune disease
• Th17 cell
• IL-23
• protein binder

Acknowledgements

The authors thank Michal Malý and Petra Kadlčáková for excellent experimental assistance and Prof. Peter Šebo for helpful discussion.

Declaration of interest

The authors report no conflicts of interest.

Funding

This work was supported by the Czech Health Research Council [AZV 16-27676A]; Czech Science Foundation [grant Nos. GAP303/10/1849 to P.M. and GA15-09157S to R.O.]; Institutional Research Concepts [RVO 86652036, RVO 61388971]; European Regional Development Fund [BIOCEV CZ.1.05/1.1.00/02.0109]; Ministry of Health and University Hospital Motol [00064203]; EU [Prague project CZ.2.16/3.1.00/24022].